SPDR S&P Biotech ETF XBI · AMEX
$149.56 -1.37% (-$2.08)
Summary
SPDR S&P Biotech ETF is an ETF - a fund traded on an exchange like a stock - run by SPDR. Positions inside: 167. The ten largest make up 18% of the fund.
- Yearly costs
- 0.35%
- Fund size
- $10.3B
- Positions
- 167
- Dividend yield
- 0.36%
- Running since
- 2006
What speaks for it
- Costs of 0.35% a year are below the middle of comparable funds (0.44%).
- Widely spread: the ten largest positions make up only 18% of the fund.
- A large fund with $10.3B under management.
- Easy to buy and sell: about $1.37B changes hands a day.
- Average yearly growth over the last ten years: 9.9%.
- It has been running since 2006.
What to watch
- 99% of the fund is in one sector (Healthcare).
- 95% of the fund is in one country (United States).
- In the last five years its price once dropped by 64% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -3.5%
- 3 months
- -0.6%
- This year
- +23%
- 1 year
- +38%
- 3 years
- +126%
- 5 years
- +21%
- 10 years
- +158%
- Avg. market cap
- $41.9B
- P/E
- -
- Forward P/E
- -
- P/S
- 9.7x
- P/B
- 6.1x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.18%
- ROIC
- -11.6%
- ROE
- -17.8%
- Gross margin
- 36.9%
- Operating margin
- -833.8%
- Net margin
- -311.9%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.10
Weighted average of the 50 largest companies, which make up 68% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Widely spread- 1 MRModerna MRNA 2.2%
- 2 NTNatera NTRA 1.8%
- 3 BIBiogen BIIB 1.8%
- 4 HAHalozyme Therapeutics HALO 1.7%
- 5 UTUnited Therapeutics UTHR 1.7%
- 6 AMAmgen AMGN 1.7%
- 7 ABAbbVie ABBV 1.7%
- 8 EXExelixis EXEL 1.7%
- 9 GIGilead Sciences GILD 1.6%
- 10 TWTwist Bioscience TWST 1.6%
Positions in the fund: 167. The ten largest make up 18% of it.
Composition as of Oct 24, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 99%
- Financials 0.7%
By country
- United States 95%
- Switzerland 1.4%
- Ireland 1.4%
- United Kingdom 1.2%
- Other countries 0.6%
By company size
- Mega cap 3.4%
- Large cap 28%
- Mid cap 51%
- Small cap 17%
- Micro cap 0.3%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (99%). Largest country: United States (95%). Largest size group: Mid cap (51%).
What does it cost me?
Cheap- A year from $10,000
- $35.00
- Over 20 years
- $1,714
From every $10,000 invested the fund takes $35.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $1,714.
How has it done?
Growing over the long run- A year on average, 10 years
- +9.9%
- Deepest drop
- -64%
- Yearly volatility
- 29%
Average yearly growth over the last ten years: 9.9%. Deepest drop in these years: 64% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 0.36%
- Payments a year
- 4
- Last payment
- $0.14
Over the last 12 months it paid $0.54 per share, which is 0.36% of today's price. The last payment was $0.14 on Jun 22, 2026.
Is it easy to buy and sell?
Very easy- Traded a day
- $1.37B
- Shares a day
- 9.1M
On an average day about $1.37B of the fund changes hands.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 47 out of 100
Weight by Bulios Fair Price
- Undervalued 28%
- Fairly valued 7.8%
- Overvalued 64%
By Fair Price, 64% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 68% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $27.3M | +31% | Reinvests | 99% |
LA LABU Direxion Daily S&P Biotech Bull 3X Shares | United States | 0.96% | $1.17B | +88% | Pays out | 68% |
TD TDNA T. Rowe Price Biotech ETF | United States | 0.55% | $9.51M | - | - | 59% |
BB BBP Virtus Biotech ETF | United States | 0.34% | $41.6M | +41% | Reinvests | 48% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.8B | +34% | Pays out | 44% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $926.0M | +40% | Reinvests | 43% |
